Author

Francisco J. Molina-Estévez

Universidad de GranadaORCID 0000-0001-9565-2199Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

Francisco Martı́niD· 2 shared Ana Hinckley-Boned· 1 shared Araceli Aguilar-GonzáleziD· 1 shared Carla PaniselloiD· 1 shared Carmen Barbero-Jiménez· 1 shared Carmen Griñán‐LisóniD· 1 shared Concha HerreraiD· 1 shared Felipe PrósperiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Francisco Martı́nORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicineNucleic Acids ResearchPeer-reviewedFeb 24, 2026

A Novel Dual-Guide CRISPR-Cas13 Strategy Improves Specificity for Single-Nucleotide Variant Detection

Araceli Aguilar-González, Ismael Martos-Jamai, Iris Ramos-Hernández…·Francisco Martı́n

This paper introduces a dual-guide CRISPR-Cas13 system that improves specificity for single-nucleotide variant detection without reducing sensitivity.

8 citationstop 1%

CRISPR screenexperimental assay

𝕏 PostBluesky

ImmunologyMolecular Therapy — Nucleic AcidsPeer-reviewedAug 15, 2024

First-in-class Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomas

Pedro Justicia-Lirio, María Tristán‐Manzano, Noelia Maldonado‐Pérez…·Francisco Martín

This paper develops doxycycline-inducible IL-18 CAR-T cells (iTRUCK19.18) that enhance antitumor activity while controlling IL-18 release through dual mechanisms.

7 citations

humanCITE-seq

𝕏 PostBluesky